Navigation Links
Interleukin Genetics Announces Strategic Divestment of Alan James Group

WALTHAM, Mass., July 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that on June 30, 2009 it executed an agreement to sell the Alan James Group assets of its subsidiary AJG Brands, Inc. to Pep Products, Inc., a subsidiary of Nutraceutical Corporation, for approximately $4.6 million in cash. The transaction was completed following the close of business on June 30th.

"While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products to the market in the past seven months, this transaction allows us to focus our efforts on growing our core genetic testing business. The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests," said Lewis H. Bender, CEO, Interleukin Genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests, including its new brand of Inherent Health genetic test products that empower consumers to maintain health and wellness, and assists pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property, and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that affect risk of heart disease, periodontal disease and osteoporosis, nutritional needs and optimal weight-loss methods, to identify nutritional and lifestyle decisions that favorably affect such conditions, to provide such information in a format tailored to the individual, and to otherwise make progress in advancing the Company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those other risks and uncertainties described in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
2. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
3. Interleukin Genetics Reports First Quarter 2009 Financial Results
4. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
7. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
8. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
9. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
10. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: